2019年冠状病毒病(COVID-19)
发病机制
炎症
医学
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
胰高血糖素样肽-1
2019-20冠状病毒爆发
兴奋剂
疾病
冠状病毒
药理学
糖尿病
生物信息学
受体
免疫学
内科学
2型糖尿病
内分泌学
病毒学
传染病(医学专业)
生物
爆发
作者
Saharnaz Sazgarnejad,Niloufar Yazdanpanah,Nima Rezaei
标识
DOI:10.1080/14787210.2021.1964955
摘要
Understanding the pathogenesis and risk factors to control the coronavirus disease 2019 (COVID-19) is necessary. Due to the importance of the inflammatory pathways in the pathogenesis of COVID-19 patients, evaluating the effects of anti-inflammatory medications is important. Glucagon-like peptide 1 receptor agonist (GLP-1 RA) is awell-known glucose-lowering agent with anti-inflammatory effects.Resources were extracted from the PubMed database, using keywords such as glucagon-like peptide-1, GLP-1 RA, SARS-CoV-2, COVID-19, inflammation, in April2021. In this review, the effects of GLP-1RA in reducing inflammation and modifying risk factors of COVID-19 severe complications are discussed. However, GLP-1 is degraded by DPP-4 with aplasma half-life of about 2-5 minutes, which makes it difficult to measure GLP-1 plasma level in clinical settings.Since no definitive treatment is available for COVID-19 so far, determining promising targets to design and/or repurpose effective medications is necessary.
科研通智能强力驱动
Strongly Powered by AbleSci AI